Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,186 result(s) found for: Antibody. Displaying page 1 of 260.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-003007-29 Sponsor Protocol Number: 2014-0087054 Start Date*: 2015-08-12
    Sponsor Name:University Hospitals Leuven, department of pediatrics
    Full Title: The Polysaccharide Antibody Response Study: Typhim Vi response and allohemagglutinins versus Pneumo 23 vaccine response in the diagnosis of Specific Polysaccharide Antibody Deficiency.
    Medical condition: Specific polysaccharide antibody deficiency.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003804-42 Sponsor Protocol Number: INCENTIVE-QIV2-EU Start Date*: 2021-10-04
    Sponsor Name:Helse Bergen HF
    Full Title: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years old
    Medical condition: Immune response to infuenza vaccine in young children
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000633-14 Sponsor Protocol Number: SZÚ/01591/2021 Start Date*: 2021-03-30
    Sponsor Name:Státní zdravotní ústav
    Full Title: DYNAMICS OF POSTVACCINATION ANTI- SARS-COV-2 ANTIBODY RESPONSE IN EMPLOYES OF THE NATIONAL INSTITUTE OF PUBLIC HEALTH AND VOLUNTARIES 1-2021
    Medical condition: antibody response following vaccine application
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10060979 Antibody test PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002946-11 Sponsor Protocol Number: 111852 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and M...
    Medical condition: Booster immunization of healthy children 4-6 years of age against diphtheria, tetanus, pertussis and polio diseases.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003370-41 Sponsor Protocol Number: VAT00002 Start Date*: 2021-08-23
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002767-95 Sponsor Protocol Number: 12/0161 Start Date*: 2013-06-17
    Sponsor Name:University College London
    Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous...
    Medical condition: Cytomegalovirus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050524 Cytomegalovirus antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002586-21 Sponsor Protocol Number: X04-MMRr-301 Start Date*: 2004-12-23
    Sponsor Name:Aventis Pasteur MSD SNC
    Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® when administered concomitantly by in...
    Medical condition: Not applicable - Healthy subjects
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001419-64 Sponsor Protocol Number: NOR-107 Start Date*: 2014-01-24
    Sponsor Name:Takeda Vaccines (Montana), Inc.
    Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004731-36 Sponsor Protocol Number: MET58 Start Date*: 2018-09-27
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in...
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FI (Completed) IT (Completed) ES (Completed) PL (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003790-10 Sponsor Protocol Number: MEQ00065 Start Date*: 2019-05-28
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2022-003286-37 Sponsor Protocol Number: D5180C00031 Start Date*: 2022-12-22
    Sponsor Name:AstraZeneca
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent I...
    Medical condition: Moderate to Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002613-34 Sponsor Protocol Number: NL76336.041.21 Start Date*: 2021-06-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome
    Medical condition: Persons with Down syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005309-18 Sponsor Protocol Number: V66_05 Start Date*: 2014-12-10
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered...
    Medical condition: Prophilaxis against diphtheria, tetanus, pertussis, hepatitis B and invasive Haemophilus influenzae type b disease.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001473-24 Sponsor Protocol Number: MET42 Start Date*: 2020-01-31
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006083-11 Sponsor Protocol Number: 110699 to 110704 Start Date*: 2009-03-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccin...
    Medical condition: Adult subjects who received a primary vaccination course with Twinrix Adult following a two-dose schedule or Twinrix Junior following a three-dose schedule as adolescents (12-15 years) approximate...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-005695-34 Sponsor Protocol Number: 106369 Start Date*: 2015-06-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II randomized, open, controlled study of the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate Plasmodium falciparum malaria vaccine RTS,S/AS01E, when incorporated into an...
    Medical condition: Primary immunization against Plasmodium falciparum malaria in healthy male and female infants aged 6 to 10 weeks at first vaccine dose, if eligible according to inclusion and exclusion criteria.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004129-27 Sponsor Protocol Number: X06-MMRV-302 Start Date*: 2006-12-13
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (...
    Medical condition: The study will involve healthy children.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002735-23 Sponsor Protocol Number: IPROTECT1 Start Date*: 2013-12-04
    Sponsor Name:InnaVirVax SA
    Full Title: Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, r...
    Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003588-73 Sponsor Protocol Number: ALXN1007-APS-201 Start Date*: 2014-07-28
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: AN OPEN-LABEL PROOF OF CONCEPT PHASE IIA TRIAL OF ALXN1007 FOR THE TREATMENT OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME
    Medical condition: Persistently aPL-positive patients with at least 1 of the following non-criteria manifestations: aPL-nephropathy, skin ulcers and/or thrombocytopenia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 13:35:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA